seekingalpha.com
Unicycive Therapeutics: Two CRLs, One Fixable Problem
Unicycive Therapeutics (UNCY) is rated as a speculative Buy with a scenario-weighted $10 price target, implying ~75% upside. FDA's second CRL was solely due to unresolved manufacturing issues; efficacy and safety remain unchallenged.